This study compares the efficacy of cetuximab and pembrolizumab versus pembrolizumab alone in the treatment of recurrent and/or metatstatic head and neck squamous cell carcinoma.
Contact phone
(517) 364-2811
Contact email
[email protected]
Principal investigator
Dr. Srkalovic, MD, PhD
Trial Category
Cancer
Trial SubCategory
Head & Neck
Webform